|Bid||1.5000 x 4000|
|Ask||2.0400 x 2200|
|Day's Range||1.9200 - 2.0000|
|52 Week Range||1.5800 - 3.2900|
|Beta (3Y Monthly)||1.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
The big shareholder groups in 22nd Century Group, Inc. (NYSEMKT:XXII) have power over the company. Large companies...
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis research, announced today the appointment of Michael J. Zercher as the Company’s Chief Operating Officer. “Since joining 22nd Century in 2016, Mike has become a highly valued member of our team providing critical leadership in several areas of our business. James W. Cornell, Director & Chairman of the Board of 22nd Century Group added, “Mike will drive our efforts to successfully bring 22nd Century’s proprietary VLNC cigarettes to market in the U.S. and internationally, as well as lead our Company’s strategic expansion in the hemp/cannabis space.
The Williamsville, New York-based company said it had a loss of 2 cents per share. The plant biotechnology company posted revenue of $6.3 million in the period. The company's shares closed at $2.21. A ...
22nd Century’s proposed VLN™ cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company filed its 2019 First Quarter Report on Form 10-Q with the U.S. Securities and Exchange Commission. The Company will provide a business update for investors on a conference call to be held Wednesday, May 8, 2019, at 4:00 PM (Eastern Time).
You may find it surprising, but the Post Office, the Atlanta Hawks and these seven marijuana stocks all have something in common. At first glance, you may think they have nothing to do with each other. After all, the Post Office is run by the government, the Atlanta Hawks are a professional basketball team and cannabis companies were established to profit off of the booming legal cannabis industry.But unfortunately, these very different organizations do in fact have something in common. And it just so happens that it is a very important thing. They are all losing money! None of them have made a profit in years!Obviously, the Post Office can continue to lose money forever because it's run by the governmental and the government can just raise taxes. And a professional sports team can continue to lose money as long as the owners are willing to sustain the losses.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut let's talk about the cannabis companies In the stock market, the idea is to invest in companies that are, or will be, profitable. This profitability will, in turn, lead to the share price appreciating. Financial theory, history and common sense all tell us that if a company doesn't make money it will eventually go out of business. Investors will see declining share prices and losses.Looking at the Cannabis Companies: You are probably familiar with the following companies if you trade or invest in the cannabis markets. They may have cool products and be in a cool industry, but if you are considering investing in them, it is important to understand that they are losing money. You may ask yourself, "how have they been able to lose money for a sustained period of time?"The answer is that they borrow money or issue stock and use these proceeds to cover their expenses. But eventually, the ability to do so will stop if they are never able to turn a profit. * 7 Strong Buy Stocks That Tick All the Boxes I am not saying that these companies will never earn money and that you can't profit by investing in their stocks. Some of them may eventually become great investments. My intent here is to express my belief that before making an investment in a company, one should consider if it is actually making money and what the future prospects of profitability are. In the long run, these dynamics will ultimately have a significant effect on the share price. Axim Biotechnologies (AXIM) Click to Enlarge Axim Biotechnologies (OTCMKTS:AXIM) makes a really cool product. It is a biotechnology company based in New York City. The company makes chewing gum that is infused with medicinal cannabis. This is used to treat pain, anxiety and other conditions. It can even be used to treat opioid addiction, which we all know is a terrible epidemic. I am not really sure how they do it because I'm a stock market guy, not a scientist, but I think it sounds like an awesome idea.But let's take a look at some numbers. Last year AXIM lost 12 cents per share. That means that for the year the company lost about $6.7 million. Unfortunately, losing money is nothing new to this company. In 2017 they lost $4.2 million, in 2016 the loss was $7.3 million, and it 2015 it was just over $10 million.Not surprisingly, the stock has not acted well. It is currently trading around the $1.50 level. As you can see on the chart, over the past year it has lost about 70% of its value. Maybe someday one of the company's product will be a huge success and it will become profitable, but over the past few years, it has certainly been a disappointment to shareholders. Americann (ACAN) Click to Enlarge Americann, Inc. (OTCMKTS:ACAN) is next on the list. Like many other cannabis companies, they are based in Denver. This company develops medical cannabis cultivation and processing properties. In other words, they build greenhouses. The greenhouses they build aren't like the kind my grandfather had in his garden. These are big-time greenhouses that are used for largescale industrial growing. They have built and developed over one million square feet of growing area.Americann has been involved with some enormous projects. Some of the projects include the Denver Medical Cannabis Center, the Massachusetts Medical Cannabis Center and the Illinois Medical Cannabis Center. The company is also committed to sustainability and uses clean energy from solar and geothermal sources. * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund Apparently, the Cannabis greenhouse business isn't very profitable -- at least in the way that Americann does it. Last year they lost $4.4 million which equates to a loss of 22 cents per share. This is more than they lost in the prior few years. In 2017 the loss was $2.7 million, in 2016 it was $2.2 million, and in 2015 the loss was $1.7 million. Maybe one day the company will be profitable but, as for now, they seem to be headed in the wrong direction. General Cannabis Corp. (CANN) Click to Enlarge General Cannabis Corp. (OTCMKTS:CANN) is a holding company that is based in Denver. They have four different segments -- security, operations, consumer goods and investments.The security segment provides different types of services to cannabis growers and retails stores. These services include video surveillance, transporting cash and providing security professionals. Consulting services to the cannabis industry that include obtaining licenses, compliance, logistics, retail operations and facility services are offered by the operations segment. The consumer goods segment includes developing relationships with apparel retailers and distributors. The investments segment provides loans and financing to companies within the cannabis industry.General cannabis is clearly an organization that is involved in many things. Maybe it is involved in too many things. Have you ever heard the expression "jack of all trades and master of none?" I think that could apply here. This company hasn't earned any money in years. Last year it lost almost $17 million, or 49 cents per share. The prior year's losses were less than half of that. In 2017, the loss was just over $8 million. In 2016, General cannabis lost just over $10 million and, in 2015, the loss was almost $9 million. If you're keeping track, this company has lost a total of $44 million in the past four years. Cannabis Sativa (CBDS) Click to Enlarge Cannabis Sativa, Inc. (OTCMKTS:CBDS) is next up on the list of losers. After looking at the company website for a while, I couldn't even figure out just what they actually do. I think it has something to do with providing services to cannabis dispensaries. Here is the description from MarketWatch:"Cannabis Sativa, Inc. engages in the research, development, acquisition and licensing of specialized natural cannabis related products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The company was founded on November 5, 2005 and is headquartered in Mesquite, NV."This company seems very mysterious to me. According to MarketWatch, there is only one employee despite having revenues that were over $500 million. One of the things that I noticed when I was looking at the financials is that the Quick Ratio is only 0.25 while the average Quick Ratio for the industry is 2.67.The Quick Ratio is the company's cash and short-term securities divided by the current liabilities. Current typically means one year or less. In other words, Cannabis Sativa only has 25 cents for each dollar of debt that they have, while the industry average is to have $2.61 for each $1 of debt. With a ratio like that, it isn't surprising that they are losing money. * 7 Energy Stocks to Buy to Light Up Your Portfolio The losses were $4.1 million in 2018, $7.6 million in 2017, $3.1 million in 2016, and $9.4 million in 2015. Tilray (TLRY) Click to Enlarge Tilray Inc. (NASDAQ:TLRY) hasn't been a publicly traded company for that long. The initial public offering was last summer. This company has the distinction of being the first publicly traded cannabis company to list on the Nasdaq. Their business model is very understandable. They engage in research, cultivation, production, and distribution of cannabis and cannabinoids. Products include dried cannabis and cannabis extracts. In other words, they grow and sell weed.Like the others, this company is losing money as well. I have heard that the cannabis markets are glutted and that the price of cannabis has fallen dramatically since its legalization. Many cannabis farmers are losing a lot of money. Maybe that is why Tilray is losing money as well.Tilray went public last year, but they have disclosed financial information going back further. If you think about it, it is kind of amazing that a company that loses money could go public. This was a common occurrence back in the dot-com era. The company has a market capitalization of around $5 billion despite the fact that they lost $67 million last year. In 2017, they lost about $8 million and had a similar size loss in 2016. 22nd Century Group (XXII) Click to Enlarge 22nd Century Group, Inc. (OTCMKTS:XXII) is based in Clarence, New York. It is a biotech company. They research and develop technologies that will allow the increase or decrease of the levels of nicotine and nicotinic alkaloids in tobacco plants and the levels of cannabinoids in cannabis plants. My guess is that there will be greater demand for increasing than decreasing. This is done through genetic engineering and plant breeding. Sounds like pretty neat stuff.But don't let their cool name and cool stock symbol fool you. They are losing money. Last year the loss was $10.4 million. That is a loss of 8 cents per share. In 2017, the annual loss was close to $17 million. The loss in 2016 was just over $15 million and the loss in 2015 was just over $14 million. * 7 Stocks Worth Buying When They're Down Maybe this company will turn around one day and become successful, but the current shareholders must be disappointed. The valuation has fallen by about one-third since December as the price per share has fallen from $3 to $2 while the broader equity markets have been booming since then. The Supreme Cannabis Co (SPRWF) Click to Enlarge The Supreme Cannabis Co, Inc. (OTCMKTS:SPRWF) is last on the list. Obviously, there are many other cannabis companies that are losing money out there, but today I just wanted to focus on these seven because they seem to be popular recently. Supreme has a similar business model as Tilray. The company grows and sells cannabis, although the product may be a little different because they say it is '"sun-grown." I suppose this is in contrast to being grown with artificial light. Supreme does this through their wholly owned subsidiary 7ACRES.Perhaps The Supreme Cannabis Company should consider changing their name to "The Subprime Cannabis Company" because it is losing money. It has seen the price of its stock fall by about 20% since September. Last year the company lost around $7.3 million. Losses in 2017 were more than twice that at $15.3 million. The loss in 2016 was $4.4 million and the loss in 2015 was about $5.7 million. Maybe the future will be better, but my guess is that The Supreme Cannabis Company's shareholders are supremely disappointed.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks to Buy to Light Up Your Portfolio * 10 Vice Stocks to Spice Up Your Portfolio * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post 7 Marijuana Stocks That Are Bleeding Cash appeared first on InvestorPlace.
22nd Century Group Inc. (NYSEAMERICAN:XXII) has announced that last week the FDA carried out a comprehensive inspection of its North Carolina manufacturing facility in line with the review of the company's Pre-Market Tobacco application for its VLN cigarettes. The proposed cigarettes are produced through 22nd Century’s proprietary Very Low Nicotine Content tobacco. VLNC cigarettes have […]The post 22nd Century Group Announces FDA Inspection For Its Pre-Market Tobacco Application appeared first on Market Exclusive.
22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that last week the U.S. Food and Drug Administration (FDA) conducted a comprehensive inspection of the Company’s manufacturing facility in North Carolina as a part of the FDA’s review of 22nd Century’s Pre-Market Tobacco (PMT) application for the Company’s VLN™ cigarettes. 22nd Century’s proposed VLN™ cigarettes are made with the Company’s proprietary Very Low Nicotine Content (VLNC) tobacco.
22nd Century Group, Inc. (NYSEMKT:XXII) shareholders might be concerned after seeing the share price drop 21% in the last quarter. But that doesn't undermine the rather lovely longer-term return, if you measure over the l...
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a world leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, today commented on a grossly misleading article published yesterday by an anonymous self-professed short seller of the Company’s stock. Publishing under the pen name “Fuzzy Panda,” the author – who will not even identify who he is – continued his baseless smear campaign against the Company in an effort to depress the share price of 22nd Century stock and to make a personal profit by duping shareholders into selling their shares. Although 22nd Century does not normally respond to “short and distort” articles or to “hit pieces,” the Company believes the grossly misleading mischaracterizations and wrongful innuendo contained in the subject article warranted a Company response.
22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today the hiring of John D. Pritchard as Vice President of Regulatory Science. Mr. Pritchard was formerly the Head of Regulatory Science for Imperial Brands, U.K. (LSE:IMB).
HENDERSON NV / ACCESSWIRE / April 11, 2019 / With the market off to its best first quarter over the past 2 decades and the cannabis industry being one of the hottest in the market, now is an ideal time ...
Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics. 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company has entered into a worldwide strategic research and development agreement with KeyGene, www.keygene.com, a global leader in plant research involving high-value genetic traits and increased crop yields. This exclusive, worldwide collaboration will focus on developing hemp/cannabis plants with exceptional cannabinoid profiles for medical and therapeutic use among other applications.
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company has issued its annual letter to shareholders as part of 22nd Century Group’s 2018 Annual Report. The 2018 letter to shareholders is reprinted below.
22nd Century Group, Inc. (NYSE American:XXII), a plant biotechnology company that is focused on tobacco harm reduction and hemp/cannabis research, announced today the results of a recently completed, company-sponsored study involving 22nd Century’s Very Low Nicotine Content (VLNC) cigarettes. The results indicate that subjects using the VLNC product had 97% less nicotine in their blood as compared to their blood-nicotine levels after use of their usual brand of highly addictive commercial cigarettes. 22nd Century’s important new study was included in the Company’s Modified Risk Tobacco Product (MRTP) application, which was previously submitted to the U.S. Food and Drug Administration (FDA) for 22nd Century’s VLNC cigarettes under the proposed brand name VLN™.
NEW YORK , March 22, 2019 /PRNewswire/ -- 22 nd Century Group (XXII) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that XXII's stock ...
NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review ...
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the March 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased 22nd Century Group, Inc. (“22nd Century” or the “Company”) (NYSE American: XXII) securities between February 18, 2016 and October 25, 2018, inclusive (the “Class Period”). 22nd Century investors have until March 22, 2019 to file a lead plaintiff motion.
LOS ANGELES, March 21, 2019 -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against 22nd Century Group,.
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of 22nd Century Group, Inc. (XXII) from February 18, 2016 through October 25, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for 22nd Century Group investors under the federal securities laws. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2019. To join the 22nd Century Group class action, go to http://pawarlawgroup.com/cases/22nd-century-group-inc/ or call Vik Pawar, Esq.
NEW YORK, March 20, 2019 -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following.